European Biotechnology Magazine

ADVERTISEMENT

ADVERTISEMENT

Erik Lundgren

multiple sclerosis

Immunic CEO: “We want to understand MS patients better than anyone”

Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy … more ➔

welcome aboard ship

AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment

AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates. more ➔

ADVERTISEMENT

stock falling down

uniQure falls as Huntington’s gene therapy shows mixed results

uniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The … more ➔

heart model plastic

AnaCardio raises €62.5M to test heart failure drug

Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient pop … more ➔

money piggybank funding

Aptadir secures €40M for gene-reactivating RNA drugs

Aptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome. more ➔

European Biotechnology

1 / 4

EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

4 / 4

EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI

NEWSLETTER

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here

Photo: Getty Images for Unsplash+

Breye raises €67.5M for diabetic eye disease trial with Novo Holdings backing

Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial. more ➔

Weight-loss pill

Novo pays up to $2.6B for Hengrui’s once-weekly obesity pill candidate

Novo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, … more ➔

ADVERTISEMENT

Sponsored Publications

1 / 2

Ute Kilger

intellectual property

G 1/25: Form over function and how expensive is it?

In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation … more ➔

2 / 2

Ponchi Kantt-Neaz, Global Executive Business Director 3PBIOVIAN

Commercial Strategy

3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business Director

The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence … more ➔

APPOINTMENTS

all appointments

EB.com_Qiagen_CEO_Jonathan_Pratt

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta Cimitan

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

tk.de_Andreas_Pahl_Heidelberg_Pharma

Simris Group AB

Simris Group AB

ADC expert appointed as CEO

Professor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris …
more ➔

spain map pushpin location

Six Spanish biotech startups to watch in 2026

The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔

ADVERTISEMENT

stop sign street

FDA keeps Newron’s evenamide trial on hold in U.S.

Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on enrollment at American sites. more ➔

gift present give back

Addex regains rights to addiction drug candidate from Indivior

Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase … more ➔

newsletter_link

EVENT

16x9

October 12 @ 11:00 - 16:00in Basel, Switzerland

Bioprocess Day, Science Connected: From R&D to Manufacturing

Bioprocess Day in Basel: an open house for everyone interested in upstream bioprocessing. Date and time: 12 October 2026, from 11 a.m. - 4 p.m, with no fixed agenda so you can join us whenever it fits your schedule. Registration is free of charge. ➔